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 STRAPLINE: DIABETES 
A predictive CD8+ T cell phenotype for T1DM progression 
 
In a cross-sectional study of individuals with type 1 diabetes mellitus, those who were 
designated to be slow disease progressors had an increased proportion of autoreactive 
islet-specific CD8+ T cells expressing an ‘exhausted’ phenotype. By contrast, rapid 
progressors had increased numbers of islet-specific CD8+ T cells with a transitional 
memory phenotype. 
Refers to Wiedeman, A.E. et al. Autoreactive CD8+ T cell exhaustion distinguishes subjects 
with slow type 1 diabetes progression. J. Clin. Invest. https://doi.org/10.1172/JCI126595 
(2019). 
At the time of type 1 diabetes mellitus (T1DM) onset, individuals have different levels of β-
cell loss, detected by measuring serum C-peptide (a by-product of insulin synthesis), which 
contributes to heterogeneity of T1DM. Furthermore, a study examining pancreatic islets by 
histology found evidence of increased loss of β-cells, increased loss of insulin staining and 
increased immune infiltration with increased numbers of intra-islet CD8+ T cells and B cells 
in individuals who developed T1DM aged <7 years1. Understanding the immunological 
factors that contribute to these differences is important to stratify different progression 
phenotypes and could inform future phenotype-dependent immunotherapies. 
In the present study, Alice Wiedeman and colleagues2 studied cryopreserved 
peripheral blood mononuclear cells from HLA-A2+ individuals (20 healthy control 
participants and 46 individuals with T1DM). The people with T1DM were stratified into two 
groups based on the serum level of C-peptide — slow and fast progression of disease at 5 
years after onset. The authors categorized individuals with <0.05 ng/ml C-peptide 5 years 
after diagnosis as rapidly progressing and individuals with >0.1 ng/ml C-peptide as slow 
progressing, regardless of the age of onset of the participants studied2.  
Mass cytometry with readout by time-of-flight (CyTOF) enables scientists to analyse a 
vast range of cell markers not hitherto possible with conventional flow cytometry. Combined 
with MHC–peptide-tetramer technology, the authors of the present study examined the very 
small subsets of antigen-specific T cells and phenotypically characterized the rare islet-
specific CD8+ T cells. Using the analytical tool, DISCOV-R, Wiedeman and co-authors 
showed that the overall frequency of islet-specific CD8+ T cells did not differ between the 
rapid and slow progressors2. However, within the islet-specific CD8+ T cell populations, the 
authors demonstrated the presence of a number of subsets based on the expression of 
previously identified cell surface and intracellular transcription markers for T cells. In 
particular, slow progressors had increased numbers of islet-specific CD8+ T cells with an 
exhausted phenotype (Figure 1). These antigen-specific exhausted CD8+ T cells expressed 
high levels of the chemokine receptor CXCR3 and the transcription factor EOMES. By 
contrast, the rapid progressors had increased numbers of islet-specific CD8+ T cells that also 
expressed CXCR3 and the regulatory HELIOS+ transitional memory phenotype (Figure 1) 2. 
Interestingly, these changes were not related to T1DM duration or age of the patients.  
Previous studies have documented a transcriptional signature indicating that exhausted 
CD8+ T cells occur as a result of a balance between stimulatory and inhibitory signals from 
other subsets of T cells, and have suggested that strategies to increase numbers of exhausted 
CD8+ T cells could be beneficial in autoimmune disease3.	 Interestingly, the present study 
suggests that the increased presence of exhausted islet-specific CD8+ T cells could slow down 
the progression of β-cell loss caused by autoimmune destruction2. CD8+ T cells with the 
exhausted phenotype are also found in tumours, where these exhausted cells are unable to kill 
the tumour cells. Furthermore, exhausted cells are seen in chronic viral infections, where the 
host is unable to mount an effective immune response	4.  
Given the emerging understanding of events leading to exhausted cells in both 
tumours and chronic infection, it is important to investigate what is occurring to other subsets 
of cells that interact with the CD8+ T cells, leading to exhaustion5. Findings from studies in 
the past few years indicate that the help of CD4+ T cells is a mechanism by which exhaustion 
is overcome. Understanding the biology of CD4+ T cells in conditions with prominent CD8+ 
T cell exhaustion could be of specific importance in relation to the current finding in T1DM, 
and CD4+ T cells might also provide a therapeutic target6. 
The observations from the careful study by Wiedeman and colleagues2 are an 
important contribution to our understanding of immunological events in the pancreas which is 
an organ that is very inaccessible. Of note, some overlap in phenotypes occurred between 
slow and rapid progressors; some slow progressors had lower numbers of exhausted islet-
specific CD8+ T cells and higher numbers of transitional HELIOS+ cells, which is similar to 
the rapid phenotype. Thus, combining phenotype studies with some functional studies is 
important, as the authors of the present study attempted to do in a subset of study participants2.  
Of note, the techniques to examine very small subsets of cells used in the present 
study2 require highly sophisticated analytical tools, which are potentially not accessible for 
many investigators and clinicians in smaller centres and/or clinics. Thus, this approach might 
not be used routinely in the near future to stratify individual patients. The finding from the 
current study is focused on individuals with an HLA-A2 haplotype, who constitute up to 50% 
of patients with T1DM. With time, more information will become available about other HLA 
types when antigenic epitopes are identified — currently only limited epitopes are available 
for HLA-A24 and B397. It will be interesting to understand if antigen-specific CD8+ T cells 
interact with other subsets of cells, including B cells and CD4+ T cells, which have also been 
found in islets1.	
In addition to the differences in disease progression rate, individual responses to 
immunotherapy at the onset of clinical T1DM are heterogeneous, which correlates with 
immune cell signatures in peripheral blood8. Thus, understanding the phenotype and 
functional processes of the underlying immune cell subsets, particularly of antigen-specific T 
cells in the individuals presenting with different speed of progression, might have an 
important bearing on the response to immunotherapy. The different rates of loss of 
endogenous β-cell function make it imperative that immunotherapeutic treatment is started as 
early as possible, particularly in rapid progressors.  
Thus far, several immunotherapeutic strategies have shown transitory effects in 
reducing the rate of loss of endogenous β-cell function after diagnosis; however, differential 
effects occur in subsets of treated individuals, which might relate to heterogeneous immune 
cell profiles. In 2019, the anti-CD3 monoclonal antibody teplizumab was found to delay 
disease onset in high risk relatives of people with T1DM9. Interestingly, response to the 
treatment correlated with increases in the number of CD8+ T cells with an exhausted 
phenotype9. Understanding the functional correlates of heterogeneous immune cell profiles 
will aid in the design of targeted therapy and in this context, promoting antigen-specific 
immune exhaustion could be of value. Moreover, the current finding2 might help to shed light 
on why anti-checkpoint therapy for cancer, which reverses an exhausted CD8+ T cell 
phenotype, has in some cases led to the development of autoimmune diabetes mellitus. This 
finding could also have important implications for testing individuals for autoimmune 
propensity and preparing them for possible autoimmunity when these cancer 
immunotherapies are used. 
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Figure 1. Characteristics of exhausted and memory T cells. Naive CD8+ T cells 
differentiate to effector cells and a subset of these effectors differentiate to memory cells. In 
addition, if there is chronic antigen stimulation and an imbalance between stimulatory and 
inhibitory stimuli, then CD8+ T cells might become exhausted4,	5 The main types of memory 
cells are designated effector memory TEM and central memory TCM, distinguished by their 
surface markers, cytokine production and their effector functions. TEM are able to respond 
with rapid effector function, while TCM self renew and are maintained as a long-lived memory 
population	10.  However, there are other subsets, including transitional memory cells 
(intermediate between TEM and TCM) and those referred to in this article also express the 
regulatory marker HELIOS.   
